Orchid Pharma Limited (ORCHPHARMA)
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation - Q1FY27
- Standalone revenue 304cr +16% y-y; EBITDA 25cr +178% y-y; PAT 12cr vs loss of 3cr y-y
- Consolidated revenue 304cr +16% y-y; PAT 3.2cr vs loss of 5.7cr y-y
- Merger of Dhanuka Laboratories effective July 2026; platform integration underway
- Multiple growth engines progressing across KSM, FDF, and innovative drugs
- FY26 standalone EBITDA and PAT revised post-merger
- Core API business positioned for long-term value creation
- No explicit forward guidance disclosed
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ORCHPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ORCHPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Orchid Pharma Limited
Important.
The summary above is generated automatically from Orchid Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.